Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anagrelide, a selective thrombocytopenic agent

M D Oertel1

  • 1Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|October 24, 1998
PubMed
Summary

Anagrelide effectively treats essential thrombocythemia by reducing platelet counts. This thrombocytopenic agent may also benefit patients with other myeloproliferative disorders, though its exact mechanism is under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synagis: an anti-RSV monoclonal antibody.

Pediatric nursing·2002
Same author

Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.

The Annals of pharmacotherapy·2001
Same author

RespiGam: an RSV immune globulin.

Pediatric nursing·1996
Same author

Ciprofloxacin-induced toxic epidermal necrolysis.

The Annals of pharmacotherapy·1996

Area of Science:

  • Pharmacology and Therapeutics
  • Hematology

Background:

  • Anagrelide is an FDA-approved agent for essential thrombocythemia.
  • Its potential role in other myeloproliferative disorders is being explored.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosing of anagrelide.
  • To assess its potential applications beyond essential thrombocythemia.

Main Methods:

  • Review of clinical trials and pharmacological data.
  • Evaluation of efficacy and safety in open-label, noncomparative studies.

Main Results:

  • Anagrelide demonstrated response rates of 60-93% in clinical trials.
  • Common adverse effects include headache, diarrhea, edema, and palpitations.

Related Experiment Videos

  • The drug is extensively metabolized with a short plasma half-life.

    • Conclusions:

    • Anagrelide is effective for essential thrombocythemia and shows promise for other myeloproliferative disorders.
    • Further research is needed to determine its place in therapy compared to agents like hydroxyurea.